-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
PP7
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/433238-84-7.gif)
| Category | Influenza Virus |
| CAS | 433238-84-7 |
| Description | PP7 is a potent inhibitor of PB1-PB2 interaction with an IC50 of 8.6 μM, and their inhibition against viral polymerase activity with an IC50 of 9.5 μM. It has antiviral activities against influenza A virus (IAV), including A(H1N1)pdm09 (EC50 = 1.4 μM), A(H7N9) and A(H9N2) subtypes. |
Product Information
| Synonyms | (4E)-1-(3,4-Dichlorophenyl)-4-(4-ethoxybenzylidene)-3,5-pyrazolidinedione; 3,5-Pyrazolidinedione, 1-(3,4-dichlorophenyl)-4-[(4-ethoxyphenyl)methylene]-, (4E)- |
| IUPAC Name | (4E)-1-(3,4-dichlorophenyl)-4-[(4-ethoxyphenyl)methylidene]pyrazolidine-3,5-dione |
| Molecular Weight | 377.22 |
| Molecular Formula | C18H14Cl2N2O3 |
| Canonical SMILES | CCOC1=CC=C(C=C1)C=C2C(=O)NN(C2=O)C3=CC(=C(C=C3)Cl)Cl |
| InChI | InChI=1S/C18H14Cl2N2O3/c1-2-25-13-6-3-11(4-7-13)9-14-17(23)21-22(18(14)24)12-5-8-15(19)16(20)10-12/h3-10H,2H2,1H3,(H,21,23)/b14-9+ |
| InChIKey | XFGORAOOZWWQKK-NTEUORMPSA-N |
| Purity | ≥95% |
| Density | 1.422±0.06 g/cm3 (Predicted) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Target | IC50: 8.6 μM (PB1-PB2 interaction) |
